AUSTRALIAN PRODUCT RECALL

APO-Cabergoline 500mcg tablets

Published 20 September 2016

Product

APO-Cabergoline is a medicine used to prevent the production of breast milk in women after giving birth, or to treat abnormally high levels of prolactin. AUST R 218126 Identifying features description Batch Number MK0903. Expiry date February 2017.

Why it was recalled

Apotex Pty Ltd is recalling one batch of the APO-Cabergoline 500mcg tablets (batch MK0903, expiry date February 2017) due to a packaging issue, where the desiccant may not protect the product from moisture throughout its shelf life.

Hazard

Failure to protect the product from moisture could lead to the product degrading over time in moist conditions. Product degradation may affect the efficacy of the product.

Read the official notice ↗

Source: Based on ACCC data or other content. ACCC © Commonwealth of Australia. ACCC-owned material is licensed under CC BY 4.0. RecallMatch extracts and formats notice information for screening. Third-party material may have separate rights. Source and reuse terms. Verify details in the official notice. RecallMatch is independent of the ACCC.